Interstitial Lung Abnormalities in Renal Transplant Recipients (LCRT)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Immunosuppressive drugs such as tacrolimus, cyclosporine, mycophenolate mofetil, sirolimus and everolimus may have toxic pulmonary effects, particularly interstitial alterations. The aim of the present study is to explore the presence of subclinical interstitial lung abnormalities in stable renal transplant recipients taking the different immunosuppressive drugs used as maintenance therapy for renal transplantation.
| Condition | Intervention |
|---|---|
|
Renal Transplantation Kidney-pancreas Transplantation |
Procedure: High-resolution CT scanning |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan |
- Subclinical lung alterations as assessed by high-resolution CT scanning [ Time Frame: CT is performed at study entry and, if abnormalities are found, it is repeated at 3-6 months ] [ Designated as safety issue: No ]
| Enrollment: | 63 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | November 2009 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Renal transplant patients |
Procedure: High-resolution CT scanning
High-resolution CT scanning
|
Detailed Description:
Prospective, cross-sectional study examining the high-resolution CT scans obtained in 63 stable renal transplant recipients taking immunosuppressive treatment for at least 24 months. The findings in patients taking the newer immunosuppressive drugs (mycophenolic acid, sirolimus and everolimus) are compared with those of the patients treated in the traditional way (cyclosporine, tacrolimus, azathioprine). All patients undergo high-resolution CT scanning.
Eligibility criteria: recipients of kidney or kidney-pancreas transplant, on immunosuppressive therapy for at least 24 months, with stable renal function and absence of any overt lung disease or lung alterations induced by other drugs, systemic diseases or occupational exposure to fibrogenic agents.
Eligibility| Ages Eligible for Study: | 18 Years to 82 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Kidney or kidney-pancreas recipients, on immunosuppressive therapy for at least 24 months
Inclusion Criteria:
- Renal transplant patients with stable renal function taking immunosuppressive therapy for at least 24 months and providing written informed consent to participate to the study
Exclusion Criteria:
- Overt lung disorders, lung toxicity due to other drugs or occupational exposure to lung-toxic agents
- Systemic connective tissue disorders or systemic vasculitis
Contacts and Locations| Italy | |
| Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital | |
| Parma, Italy, 43100 | |
| Principal Investigator: | Carlo Buzio, MD | University of Parma |
More Information
No publications provided
| Responsible Party: | Carlo Buzio, University of Parma |
| ClinicalTrials.gov Identifier: | NCT01017757 History of Changes |
| Other Study ID Numbers: | LungCtRenalTx |
| Study First Received: | November 18, 2009 |
| Last Updated: | November 20, 2009 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by University of Parma:
|
Interstitial lung disease Immunosuppressive therapy Renal transplant |
Additional relevant MeSH terms:
|
Congenital Abnormalities |
ClinicalTrials.gov processed this record on May 19, 2013